Current-day precision oncology: From cancer prevention, screening, drug development, and treatment - Have we fallen short of the promise?

Current Opinion in Oncology

Volumn 28, Issue 5, 2016, Pages 441-446

  Morgan, Gilberto ^a   Aftimos, Philippe ^b   Awada, Ahmad ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

DNA; next generation sequencing; oncogenes; precision oncology; tumor suppressor genes

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER SCREENING; HUMAN; NEOPLASM; NEXT GENERATION SEQUENCING; ONCOLOGY; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SOCIETY; DRUG DESIGN; EARLY CANCER DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; TRENDS;

DRUG DESIGN; EARLY DETECTION OF CANCER; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PRECISION MEDICINE;

EID: 84978726674     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000318     Document Type: Review

References (30)

1. Hussain MR, Baig M, Mohamoud HS, et al. BRAF gene: From human cancers to developmental syndromes. Saudi J Biol Sci 2015; 22: 359-373.
2. Aftimos P, Barthelemy P, Awada A. Molecular biology in medical oncology: diagnosis, prognosis and precision medicine. Discov Med 2014; 17: 81-91.
3. Madl KD, Kohane IS. Time for a patient-driven health information economy. N Eng J Med 2016; 374:205.
4. Jameson L, Longo D. Precision medicine-personalized, problematic and promising. N Engl J Med 2015; 372:2229-2234.
5. Mirnezami R, Nicholson J. Preparing for precision medicine. N Eng J Med 2012; 366:489-491.
6. Bougie O, Weberpals JI. Clinical considerations of BRCA1-And BRCA2-mutation carriers: a review. Int J Surg Oncol 2011; 2011: Article ID 374012.
7. Barlas S. Precision medicine initiative aims for a new generation of diagnostics and treatments. P T 2015; 40:340-342; 352.
8. Mendes E. Personalized cancer prevention. Cancer.org, 3 April 2015.
9. Rabybenjamin. Personalized medicine. Up to Date 2016.
10. Do K, O'Sullivan Coyne G, Chen AP. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Chin Clin Oncol 2015; 4:31.
11. Francois T, Christine D, Aftimos P, et al. Impact of tumor sequencing on the use of anticancer drugs. Curr Opin Oncol 2014; 26:347-356.
12. Stadler Z, Schrader K, Vijai J, et al. Cancer genomics and inherited risk. J Clin Oncol 2014; 32:687-698.
13. Golubovskaya VM, Cance WG. Targeting the p53 pathway. Surg Oncol Clin N Am 2013; 22:747-764.
14. Langreth R. Fumbled DNA tests mean peril for Breast-Cancer patients. Bloomberg 9 September 2012.
15. Gingras I, Sonnenblick A, de Azambuja E, et al. The current use and attitudes towards tumor genome sequencing in breast cancer. Sci Rep 2016; 6:22517.
16. Gray S, Hucks-Courant K, Cronin A, et al. Physicians? attitudes about multiplex tumor genomic testing. J Clin Oncol 2014; 32:1-6.
17. Chau NG, Lorch JH. Exceptional responders inspire change: lessons for drug development from the bedside to the bench and back. Oncologist 2015; 20:699-701.
18. IyerG, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338:221.
19. Prasad V, Vandross A. Characteristics of exceptional or super responders to cancer drugs. Mayo Clin Proc 2015; 90:1639-1649.
20. Collins F, Varmus H. A new initiative on precision medicine. N Eng J Med 2015; 372:9.
21. Biankin AV, Piantadosi S, Hollingsworth SJ. Patient-centric trials for therapeutic development in precision oncology. Nature 2015; 526: 361-370.
22. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and germline BRCA1/2 mutation. J Clin Oncol 2016; 33:244-250.
23. Watson IR, Takahashi K, Andrew Futreal P, et al. Emerging patterns of somatic mutations in cancer. Nat Rev Genet 2013; 14:703-718.
24. Schwarzenbach H, Müller V, Milde-Langosch K, et al. Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst 2011; 7:2848-2854.
25. Awada A, Aftimos P. Targeted therapies of solid cancers: new options, new challenges. Curropin Oncol 2013; 25:296-304.
26. Fleeman N, Bagust A, Dundar Y. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer. Pharmacoeconomics 2015; 33:13-23.
27. Payne PR, Lussier Y, Embi PJ. Rethinking the role and impact of health information technology: informatics as an interventional discipline. MC Med Inform Decis Mak 2016; 16:40.
28. Ito A, Kondo S, Tada K, Kitano S. Clinical development of immune checkpoint inhibitors. Biomed Res Int 2015; 2015:605478.
29. McGranahan N, Furness A, Rosenthal R, et al. Clonal antigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351.
30. Wang X. Cancer Moonshot 2020: a new march of clinical and translational medicine. Clin Transl Med 2016; 5:11.